France moves forward on pharmacovigilance overhaul
This article was originally published in SRA
As part of its ongoing review into the French pharmacovigilance and regulatory system, France's General Inspectorate of Social Affairs, IGAS, has met with the European Medicines Agency to discuss pharmacovigilance in the EU1. IGAS's review is expected to lead to an overhaul of the current system and considerable change for pharmaceutical companies.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.